ReviewJournal of neuro-oncology2022
Leptomeningeal metastases: the future is now.
Review in Journal of neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07559097 (A Phase I/II, Single-arm, Single-center Clinical Study), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II, Single-arm, Single-center Clinical Study: Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients.Frontiers in oncology · 2025Pooled it
- Trial
- Clinical predictors of leptomeningeal metastasis from lung adenocarcinoma based on retrospective analysis.Oncology letters · 2026Article
- Article
- Advances in Ommaya reservoir-based intrathecal therapy for leptomeningeal metastasis from non-small cell lung cancer: a systematic review.Frontiers in oncology · 2026Review
- Intrathecal sintilimab for leptomeningeal metastases of non-small cell lung cancer failed from targeted therapy and intrathecal chemotherapy (LMIS study).Neuro-oncology · 2025Article
- Review
- HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen.CNS oncology · 2023Article
- Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report.CNS oncology · 2023Article
- Diagnostic and Therapeutic Updates in Leptomeningeal Disease.Current oncology reports · 2023Review
- Cerebrospinal fluid-administered therapies for leptomeningeal metastases from solid tumors.Future oncology (London, England) · 2023Review
- The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non-Small Cell Lung Cancer.Clinical Medicine Insights. Oncology · 2023Review
- Novel Therapeutic Approaches in Neoplastic Meningitis.Cancers · 2022Review
- Visual loss as the initial manifestation of an ignored disseminated prostate cancer: A case report.American journal of ophthalmology case reports · 2022Article
- Utility of cerebrospinal fluid circulating tumor cell quantification and next-generation sequencing in patients with suspicion for leptomeningeal disease.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastases (LM) constitute an involvement of cancer which is associated with marked morbidity and mortality. The contemporary diagnostic and therapeutic management of LM from solid tumors is reviewed. Therapeutic modalities including systemic therapies, cerebrospinal fluid (CSF)-directed therapies, and radiation therapy are discussed. This is to provide context for how the field of LM management may evolve in the near term. The future directions currently undergoing investigation for diagnostic, response assessment, and therapeutic purposes are highlighted. This is done within the context of the pathophysiology of the disease. Specifically the role of CSF circulating tumor cells and cell free circulating tumor DNA in diagnosis and response assement are reviewed. Novel therapeutic approaches across a range of modalities are discussed. Numerous ongoing studies which have the potential to alter the management of LM are referenced.
Indexed as
Identifiers
35048267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.